News stories about Vitamin Shoppe (NYSE:VSI) have been trending somewhat negative recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vitamin Shoppe earned a daily sentiment score of -0.04 on Accern’s scale. Accern also gave media coverage about the specialty retailer an impact score of 47.4050633935334 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Vitamin Shoppe (NYSE VSI) traded down $0.05 on Tuesday, hitting $3.80. The stock had a trading volume of 561,847 shares, compared to its average volume of 520,445. The stock has a market cap of $87.52, a P/E ratio of 3.92 and a beta of 0.69. The company has a current ratio of 2.07, a quick ratio of 0.32 and a debt-to-equity ratio of 0.59. Vitamin Shoppe has a fifty-two week low of $2.95 and a fifty-two week high of $26.25.
Vitamin Shoppe (NYSE:VSI) last released its quarterly earnings results on Wednesday, November 8th. The specialty retailer reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.20). The firm had revenue of $288.20 million for the quarter, compared to analysts’ expectations of $297.61 million. Vitamin Shoppe had a positive return on equity of 6.17% and a negative net margin of 20.27%. The company’s quarterly revenue was down 8.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.50 EPS. analysts forecast that Vitamin Shoppe will post 0.44 EPS for the current year.
VSI has been the topic of several recent analyst reports. ValuEngine raised Vitamin Shoppe from a “hold” rating to a “buy” rating in a research note on Thursday, October 5th. Bank of America reissued an “underperform” rating and set a $5.00 target price (down previously from $5.50) on shares of Vitamin Shoppe in a research note on Wednesday, August 23rd. Morgan Stanley set a $8.00 target price on Vitamin Shoppe and gave the stock a “hold” rating in a research note on Thursday, August 10th. Zacks Investment Research raised Vitamin Shoppe from a “sell” rating to a “hold” rating in a research note on Wednesday, October 25th. Finally, Barclays cut their price target on Vitamin Shoppe from $13.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, August 10th. Four equities research analysts have rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company. Vitamin Shoppe has an average rating of “Hold” and a consensus target price of $5.00.
ILLEGAL ACTIVITY WARNING: “Vitamin Shoppe (NYSE:VSI) Receives Daily Media Sentiment Rating of -0.04” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/05/somewhat-critical-media-coverage-somewhat-unlikely-to-impact-vitamin-shoppe-vsi-share-price.html.
Vitamin Shoppe Company Profile
Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.
Receive News & Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related companies with MarketBeat.com's FREE daily email newsletter.